Thromboembolic toxicity observed with concurrent trametinib and
lenalidomide therapy
- Priya Chan,
- Ashley Sabus,
- Molly Hemenway,
- Kathryn Chatfield,
- Christina White ,
- David Mirsky,
- Nicholas Foreman,
- Nathan Dahl
Molly Hemenway
University of Colorado - Anschutz Medical Campus
Author ProfileKathryn Chatfield
University of Colorado - Anschutz Medical Campus
Author ProfileChristina White
University of Colorado - Anschutz Medical Campus
Author ProfileDavid Mirsky
University of Colorado - Anschutz Medical Campus
Author ProfileNicholas Foreman
University of Colorado - Anschutz Medical Campus
Author ProfileNathan Dahl
University of Colorado - Anschutz Medical Campus
Author ProfileAbstract
The event-free survival of pediatric low-grade gliomas is poor, and
patients often require multiple treatment strategies. While MEK and RAF
inhibitors are efficacious in early-phase trials, not all patients
respond and many experience progression following completion of therapy.
Evaluating combination therapies that may enhance efficacy or prolong
disease stabilization is warranted. We report our institutional
experience using concurrent trametinib and lenalidomide in the treatment
of primary pediatric central and peripheral nervous system tumors. Two
of four patients using this combination therapy experienced severe
thromboembolic events necessitating discontinuation of therapy. This
combination requires further investigation, and we urge caution if used.25 Apr 2022Submission Checks Completed 25 Apr 2022Assigned to Editor
25 Apr 2022Submitted to Pediatric Blood & Cancer 24 May 2022Reviewer(s) Assigned
12 Jun 2022Review(s) Completed, Editorial Evaluation Pending
14 Jun 2022Editorial Decision: Revise Minor
02 Sep 2022Submission Checks Completed
02 Sep 2022Assigned to Editor
02 Sep 20221st Revision Received
13 Dec 2022Review(s) Completed, Editorial Evaluation Pending
13 Dec 2022Editorial Decision: Accept